Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: Long-term follow-up of a single centre cohort

Alimentary Pharmacology and Therapeutics

Volumn 32, Issue 9, 2010, Pages 1129-1134

  Waugh, A W G ^a   Garg, S ^b   Matic, K ^c   Gramlich, L ^c   Wong, C ^c   Sadowski, D C ^c   Millan, M ^d   Bailey, R ^c   Todoruk, D ^c   Cherry, R ^d   Teshima, C W ^a   Dieleman, L ^a   Fedorak, R N ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA HOSPITAL   (Canada)

^c ROYAL ALEXANDRA HOSPITAL   (Canada)

^d Misericordia Community Hospital   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MESALAZINE; METHOTREXATE;

ADULT; ARTICLE; CLINICAL PRACTICE; CLINICAL PROTOCOL; COHORT ANALYSIS; CORTICOSTEROID THERAPY; CROHN DISEASE; DISEASE ACTIVITY; DISEASE COURSE; DRUG CHOICE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH INSURANCE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; RELAPSE; REMISSION; SERUM SICKNESS; TREATMENT FAILURE; TREATMENT RESPONSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CROHN DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; REMISSION INDUCTION; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 78649465120     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04446.x     Document Type: Article

References (21)

1. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
2. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 1999; 340: 1398-405.
3. Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004; 126: 402-13.
4. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-85.
5. Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
6. Schnitzler F, Fidder H, Ferrante M, et al. Long-term outcome of treatment with infliximab in 614 patients with Crohn's disease: results from a single-centre cohort. Gut 2009; 58: 492-500.
7. Teshima CW, Thompson A, Dhanoa L, Dieleman LA, Fedorak RN. Long-term response rates to infliximab therapy for Crohn's disease in an outpatient cohort. Can J Gastroenterol 2009; 23: 348-52.
8. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients withearly rheumatoid arthritis (the BeStstudy): a randomized, controlled trial. Arthritis Rheum 2005; 52: 3381-90.
9. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. Mod Rheumatol 2008; 18: 460-4.
10. Louis E, Vernier-Massouille G, Grimaud JC, et al. Infliximab discontinuation in Crohn's disease patients in stable remission on combined therapy with immunosuppressors: a prospective ongoing cohort study. Gastroenterology 2009; 136(Suppl 1): A-146.
11. Panaccione R, Fedorak RN, Aumais G, et al. Canadian Association of Gastroenterology Clinical Practice Guidelines: the use of infliximab in Crohn's disease. Can J Gastroenterol 2004; 18: 503-8.
12. Hoentjen F, van Bodegraven AA. Safety of anti-tumor necrosis factor therapy in inflammatory bowel disease. World J Gastroenterol 2009; 15: 2067-73.
13. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126: 1593-610.
14. Lemann M, Mary JY, Duclos B, et al. Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebocontrolled trial. Gastroenterology 2006; 130: 1054-61.
15. Burton PR, Clayton DG, Cardon LR, et al. for the Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 2007; 447: 661-78.
16. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008; 40:955-62.
17. Libioulle C, Louis E, Hansoul S, et al. Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet 2007; 3: e58.
18. Parkes M, Barrett JC, Prescott NJ, et al. Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nat Genet 2007; 39: 830-2.
19. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut 2009; 58: 1612-9.
20. Sekiguchi N, Kawauchi S, Furuya T, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. Rheumatology (Oxford) 2008; 47: 780-8.
21. Schnitzler F, Fidder H, Ferrante M, et al. Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease. Inflamm Bowel Dis 2009; 15: 1295-301.